This invention is generally related to novel compositions and methods for treating or preventing fibrosis, diseases or disorders associated with fibrosis, neurodegeneration, diseases or disorders associated with neurodegeneration and cardiovascular disease or disorders.

Provided herein are compositions and methods for down-regulating mTORC1 signaling in a subject, comprising administering to the subject an effective amount of one or more compositions that promote increased levels or activity of CIB32 or a biologically active fragment or variant thereof in the subject.

Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration.

Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration.

The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.

The present invention relates to therapeutic methods, uses and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lymphatic system, particularly lymphedema.

The present invention relates to therapeutic methods, uses and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lymphatic system, particularly lymphedema.

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

Compositions, kits, and systems are disclosed that include calreticulin gene delivering nanoparticles that can be used alone or in combination with focused ultrasound to induce immunogenic cell death in tumors. Also disclosed are methods of producing and using the compositions, kits, and systems.

Provided are compositions including a CPNE4 protein or a polynucleotide encoding thereof, a pharmaceutical composition, a quasi-drug composition, a dietary supplement, and a health functional food composition. A method for preventing or treating dentin-dental disease or periodontal disease and a method and a method for promoting regeneration of hard tissue including dentin, bone and cementum, and/or pulp tissue are disclosed.